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background:  Reduced left ventricular ejection fraction (LVEF) post ST-elevation myocardial infarction (STEMI) is associated with 
thromboembolic events. Triple therapy (TRT), oral anticoagulant therapy with dual antiplatelet therapy (DAPT), is frequently used in 
patients undergoing percutaneous coronary interventions (PCI). This study examined long-term safety and efficacy of TRT in STEMI post 
PCI with reduced LVEF.
methods:  STEMI patients post PCI with new onset reduced LVEF (<40%) and sinus rhythm were identified in a prospective PCI registry. 
Baseline characteristics and long-term outcomes were compared between patients receiving DAPT alone and TRT.
results:  Baseline characteristics were similar between patients on TRT (n=180) and on DAPT (n=1510). TRT groups were more likely to 
present with shock, need mechanical support, and have higher peak troponin levels and longer hospital stays. No significant differences 
were seen between the 2 groups in death rates; major cardiovascular adverse events; MI; target vessel revascularization; and target lesion 
revascularization at 1 and 6 months and at 1, 2, and 3 years. However, in this cohort, TRT did not significantly increase major bleeding 
(2.8% vs. 2.5%, p=0.5) or hematoma rates (0.6% vs. 0.3%, p=0.5) compared to DAPT.
Conclusion:  TRT did not change long-term ischemic outcomes in patients undergoing PCI for STEMI with new onset low EF, compared to 
DAPT. Given the risk of more bleed with TRT, their routine use in this population should be revisited.
 
